[Neuronal effects and biomarkers of antidepressant treatments : Current review from the perspective of neuroimaging].
Depression is one of the most frequent and disabling mental disorders worldwide and is accompanied by a severe impairment in the quality of life. There are numerous imaging studies showing differences in the volume of gray and white brain matter and function between patients suffering from depression and healthy controls. Neuroimaging studies show that pharmacotherapy and electroconvulsive therapy are accompanied by an increase of hippocampal gray matter volume while as a result of psychotherapy activity changes in the anterior cingulate cortex (ACC) have repeatedly been reported. By the identification of neuroanatomical markers, baseline volumes of the ACC have also been shown to be associated with therapy response to all treatments. The identification of such neuronal biomarkers in combination with machine learning techniques provide a promising step towards a neurobiologically based application for the prediction of treatment response.